

Special Issue

Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases

Message from the Guest Editors

In the last two decades, the number of people living with neurodegenerative disorders has raised due to increased aging of world population, and their social and economic burden has become a major health issue.

This notwithstanding, despite the great efforts dedicated to the identification new therapeutic targets and development of innovative disease-modifying agents, we still miss effective approaches able to halt or delay symptom progression and neurodegeneration in the brain of patients affected by these highly disabling conditions.

The aim of this Special Issue is to collect the latest research on novel therapeutic targets, as well as innovative deliveries or formulations, for the design and pharmacological characterization of disease-modifying agents, counteracting neuronal loss, exerting neuroprotection or reducing pathological protein aggregates in neurodegenerative diseases.

Guest Editors

Dr. Francesca Longhena

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy

Dr. Valentina Straniero

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Luigi Mangiagalli, 25, 20133 Milan, Italy

Deadline for manuscript submissions

closed (30 November 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/180567

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).